Biomedical subjects

P Jantscheff

Publications and source records attributed to P Jantscheff.

31 records · Page 2Linked to original sources

PubMed1986

Different E-rosetting properties of human peripheral blood NK- and K-cells.

Mononuclear, non-adherent blood leukocytes were separated into the spontaneously E-rosetting (E+) and non-E-rosetting (E-) fraction. NK- and K-cell activity was determined simultaneously in a 4 h assay against 51Cr-labeled K 562 cell line cells and rabbit antiserum coated mouse leukemia cells (Gr/E) respectively. In each case E- exhibited a significantly higher K-cell activity than E+ [M16 donors E-:E+ = 46 +/- 11:10 +/- 6 (% specific cytotoxicity)]. With regard to NK-cell activity E- of only 7 donors was significantly more active than E+ [M7 donors E-:E+ = 49 +/- 15:20 +/- 10]. Six times the activities of the two fractions were not significantly different [M6 donors E-:E+ = 46 +/- 15:39 +/- 14]. On the other hand E+ of 3 donors displayed a significantly stronger activity than E-[M3 donors E-:E+ = 13 +/- 10:36 +/- 9]. These results confirm the heterogeneity of NK-cells with respect to E-rosetting properties and indicate that NK- and K-cells of at least 3 donors may belong to different cellular subsets [NK:E- less than E+; K:E- greater than E+].

Animals↗

PubMed1985

Monoclonal antibodies against the human leukemia cell line K 562.

Three monoclonal antibodies raised against K 562, a cell line originally established from a patient with chronic myeloid leukemia (CML) in terminal blast crisis, were selected according to their distinct reaction pattern. Whereas two antibodies (ZIK-C1-A/C5 and ZIK-C1-A/H5 also designated C and H) recognized antigens, present on K 562 cells and other immature and mature hematopoietic cells (cell lines and normal blood and bone marrow cells), antibody ZIK-C1-A/D9 also designated Y showed an exclusive binding to K 562 cells. The results obtained (here and in the following paper) indicate, that antibody ZIK-C1-A/D9 defines an early differentiation antigen of hematopoiesis or a leukemia-associated antigen.

Antibodies, Monoclonal↗

PubMed1983

NK and K cells in malignant lymph nodes.

Explore the source record for details and available documents.

Cell Line↗

PubMed1982

[Human nonspecific killer cells].

The NK and K-cell activity of human leukocytes was investigated as compared with those cells of the K 562 cell line and murine cells covered by xenoantibodies in Graffi erythroblast leukaemia by means of the 51Cr release test. NK and K-cells could be identified in the blood and bone-marrow. However, they could not be identified in the thymus, lymph-nodes, and tonsils. Attempts of cell fraction with the blood of healthy donors revealed that the K-cells must be attributed to non-T-lymphocytes. NK-cells may be found in the fraction of non-T-lymphocytes as well as in that of T-lymphocytes. Killer cell activity tests in children with acute leukaemia resulted in leukaemia cells having NK and K-cell activity only in very rare cases. ALL patients in remission had strongly lowered NK-cell values under chemotherapy. In comparison to that, chemotherapy had no influence on K-cell activity. On the one hand, NK-cell activities were induced in mixed cultures of allogenous lymphocytes of the blood and, on the other hand, in cells of lymph-nodes. Attempts of fractionation, investigations for determining the influence of chemotherapy and attempts of inducing killer cell activity in vitro lead to the conclusion that NK and K-cells may be regarded as similar cell populations, being, however, not identical.

Acute Disease↗

PubMed1981

Acute leukemia and nonspecific killer cells.

Explore the source record for details and available documents.

Acute Disease↗

PubMed1980

[Subtypification of acute lymphocytic leukaemia (ALL) in childhood by characterization of immunological surface membrane markers (author's transl)].

Leukaemic blast cells isolated from bone marrow or blood of 42 children with ALL were investigated for presence of immunological surface membrane markers. By characterization of 5 surface markers (reaction with an anti-ALL serum for demonstration of a leukaemia-associated antigen, reaction with an anti-thymocyte serum and formation of E-rosettes for demonstration of T-lymphozytes, as well as reaction with an anti-Ig serum and formation of EAC-rosettes for demonstration of B-lymphocytes) the ALL cells of the 42 patients could be divided into 5 subtypes: I. 18 patients (42,7%( O-ALL with common ALL antigen II. 13 patients (31%) O-ALL without common ALL antigen III. 7 patients (16,7%) T-ALL with E-rosette formation IV. 3 patients (7,2) T-ALL without E-rosette formation V. 1 patients (2,4%) B-ALL.

Adolescent↗

PubMedDate not supplied

Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors.

On the basis of compelling preclinical data in cats and dogs, we initiated a clinical gene therapy study in nine patients with advanced solid tumors using xenogeneic fibroblasts secreting human interleukin (IL)-2 (Vero-IL-2 cells). Cohorts of three successive patients with tumors accessible to computed tomography- or ultrasound-guided injection were treated repeatedly with 5 x 10(5), 5 x 10(6), or 5 x 10(7) Vero-IL-2 cells. The endpoints of the study were feasibility, toxicity, and the clinical and biological effects of this novel approach to immunotherapy of cancer. Histopathological, immunological, and molecular analyses were performed on biopsy specimens of tumors and blood samples before, during, and after treatment. Treatment was well tolerated, and toxicity consisted of transient fever in one patient and short-lived, mild itching and erythema in two others. One patient with soft-tissue sarcoma showed a reduction of >90% and >50% of the volume of two distant, noninjected metastases, lasting for 29+ and 26 months, respectively. Four other patients showed stabilization of their disease for 3-9 months; of these patients, one with melanoma developed marked vitiligo. We conclude that repeated injections of < or =5 x 10(7) Vero-IL-2 cells are feasible and safe in heavily pretreated patients with advanced solid tumors. An additional evaluation of an intratumoral application of Vero-IL-2 seems warranted.

Adult↗

PubMedDate not supplied